QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QL-401’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

QL-401 overview

QL-401 is under development for the treatment of locally advanced, recurrent or metastatic solid tumors or hematological tumors including relapsed acute myeloid leukemia, refractory acute myeloid leukemia, myelodysplastic syndrome and peripheral T-cell lymphomas (PTCL). It is a bi-specific monoclonal antibody and acts by targeting leukocyte surface antigen (CD47)  and PD-L1.

For a complete picture of QL-401’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.